Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PRNP | P04156 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832927 | 0.79 | KDM4E (0.31) | ALDH1A1KDM4ELMNAPRNPNPSR1 | |
| SCHEMBL25670600 | 0.78 | LMNA (0.35) | ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL10139179 | 0.76 | ALDH1A1 (0.47) | ALDH1A1KDM4ELMNAPRNPRXFP1 | |
| SCHEMBL10171939 | 0.76 | POLB (0.54) | ALDH1A1KDM4ELMNAPRNPNPSR1 | |
| SCHEMBL14985883 | 0.76 | GPR3 (0.55) | ALDH1A1KDM4ELMNAPRNPNPSR1 | |
| SCHEMBL179260 | 0.76 | LMNA (0.49) | ALDH1A1KDM4ELMNAPRNPNPSR1 | |
| SCHEMBL12142339 | 0.75 | GPR3 (0.54) | ALDH1A1KDM4ELMNATSHRHPGD | |
| SCHEMBL12397278 | 0.75 | HCAR2 (0.35) | ALDH1A1KDM4ELMNATSHRATM | |
| SCHEMBL24067370 | 0.74 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNANPSR1TSHR | |
| Ammonia Solution, Strong SCHEMBL28418689 | 0.74 | POLB (0.53) | ALDH1A1KDM4ELMNAPRNPNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ALDH1A1 3233/4885KDM4E 3368/4885LMNA 2878/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | ALDH1A1 316/4885KDM4E 923/4885LMNA 4480/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ALDH1A1 316/4885KDM4E 923/4885LMNA 4480/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | ALDH1A1 2351/4885KDM4E 4347/4885LMNA 2858/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | ALDH1A1 4801/4885KDM4E 3971/4885LMNA 3267/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ALDH1A1 3233/4885KDM4E 3368/4885LMNA 2878/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ALDH1A1 3233/4885KDM4E 3368/4885LMNA 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.